MIM
KALV

MetLife Investment Management’s KalVista Pharmaceuticals KALV Stock Holding History

MetLife Investment Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$437K Hold
21,688
– – ﹤0.01% 1822
2025
Q4 		$350K Hold
21,688
– – ﹤0.01% 1965
2025
Q3 		$264K Hold
21,688
– – ﹤0.01% 2156
2025
Q2 		$245K Hold
21,688
– – ﹤0.01% 2078
2025
Q1 		$250K Buy
21,688
+2,536
+13% +$25.9K ﹤0.01% 2081
2024
Q4 		$162K Sell
19,152
-3,137
-14% -$32.5K ﹤0.01% 2406
2024
Q3 		$258K Hold
22,289
– – ﹤0.01% 2154
2024
Q2 		$263K Buy
22,289
+5,513
+33% +$64.3K ﹤0.01% 2077
2024
Q1 		$199K Hold
16,776
– – ﹤0.01% 2205
2023
Q4 		$206K Buy
16,776
+4,281
+34% +$38.9K ﹤0.01% 2230
2023
Q3 		$120K Hold
12,495
– – ﹤0.01% 2486
2023
Q2 		$112K Hold
12,495
– – ﹤0.01% 2606
2023
Q1 		$98.2K Hold
12,495
– – ﹤0.01% 2561
2022
Q4 		$84.5K Hold
12,495
– – ﹤0.01% 2659
2022
Q3 		$181K Hold
12,495
– – ﹤0.01% 2359
2022
Q2 		$123K Hold
12,495
– – ﹤0.01% 2614
2022
Q1 		$184K Buy
12,495
+6,365
+104% +$91.4K ﹤0.01% 2396
2021
Q4 		$81.1K Hold
6,130
– – ﹤0.01% 2452
2021
Q3 		$107K Hold
6,130
– – ﹤0.01% 2416
2021
Q2 		$147K Hold
6,130
– – ﹤0.01% 2335
2021
Q1 		$157K Sell
6,130
-963
-14% -$25.3K ﹤0.01% 2172
2020
Q4 		$135K Buy
+7,093
New +$122K ﹤0.01% 2168
2019
Q3 		– Sell
-6,284
Closed -$139K – 2361
2019
Q2 		$139K Buy
+6,284
New +$147K ﹤0.01% 2228

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's KALV Position: Q1 2026 in Review

MetLife Investment Management held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 21,688 shares worth $437K. The position accounts for ﹤0.01% of the portfolio, ranked #1822.

MetLife Investment Management first reported a position in KALV in Q2 2019 and has held it in 23 quarters since. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • MetLife Investment Management held 21,688 shares of KalVista Pharmaceuticals worth $437K as of Q1 2026.
  • MetLife Investment Management left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1822 holding.
  • MetLife Investment Management first reported a position in KalVista Pharmaceuticals in Q2 2019 and has held it in 23 quarters since.
  • 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.